{"id":8461,"date":"2018-02-23T09:00:03","date_gmt":"2018-02-23T09:00:03","guid":{"rendered":"https:\/\/www.acarix.com\/medtech-specialist-acarix-ab-names-christian-lindholm-as-interim-ceo-2\/"},"modified":"2024-11-18T19:06:09","modified_gmt":"2024-11-18T19:06:09","slug":"medtech-specialist-acarix-ab-names-christian-lindholm-as-interim-ceo-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/medtech-specialist-acarix-ab-names-christian-lindholm-as-interim-ceo-2\/","title":{"rendered":"Medtech specialist Acarix AB names Christian Lindholm as Interim CEO"},"content":{"rendered":"
<\/strong><\/div>\n

Press release<\/p>\n

Malmö, February 23, 2018<\/p>\n

Medtech specialist Acarix AB names Christian Lindholm as Interim CEO<\/strong><\/p>\n

Acarix AB (publ) (“Acarix”), developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of the company’s current CFO, Christian Lindholm as interim Chief Executive Officer. Lindholm replaces CEO Søren Rysholt Christiansen who announced his resignation on November 6th, 2017.<\/strong><\/p>\n

“I am confident that Christian, who has been with the company and served in the management team as CFO since June 2017, will ensure a seamless transition of the leadership until a permanent CEO has been established”, said Dr. Werner Braun, chairman of Acarix.<\/p>\n

Christian Lindholm will serve as interim Chief Executive Officer while the Board of Directors continue the work to establish a permanent solution.<\/p>\n

Christian Lindholm has during the last 17 years held positions as CFO within both private and listed companies. Prior to joining Acarix in 2017, Christian was CFO at Doro AB and TFS International AB.<\/p>\n

Contacts:<\/strong><\/p>\n

Dr. Werner Braun, Chairman of the Board, E-mail: info@acarix.com, Phone: +49 151 70 131 343<\/p>\n

Christian Lindholm, interim Chief Executive Officer, E-mail: secli@acarix.com, Phone: +46 705 118 333<\/p>\n

Notes to editors:<\/strong><\/p>\n

Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team.<\/p>\n

The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.<\/p>\n

See more at www.acarix.com<\/a>.<\/p>\n

Press release interim CEO ENG.<\/a><\/p>\n

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire<\/em><\/p>\n

<\/div>\n